Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
NASDAQ:TBPH
Holding TBPH?
Track your performance easily
TBPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.44 - $11.71
Previous Close$9.25
Volume91.40K
Average Volume (3M)196.16K
Market Cap
$454.86M
Enterprise Value$408.48M
Total Cash (Recent Filing)$91.36M
Total Debt (Recent Filing)$44.98M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Mar 03, 2025EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding49,174,296
10 Day Avg. Volume246,382
30 Day Avg. Volume196,158
Standard Deviation0.13
R-Squared0.00964
Alpha-0.00550
Financial Highlights & Ratios
Price to Book (P/B)2.64
Price to Sales (P/S)7.72
Price to Cash Flow (P/CF)-23.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.46
Enterprise Value/Gross Profit7.11
Enterprise Value/Ebitda-12.72
Forecast
1Y Price Target
$11.25Price Target Upside21.62% Upside
Rating ConsensusHold
Number of Analyst Covering4
Theravance Biopharma News
PremiumCompany Announcements
Theravance Biopharma’s Third Quarter 2024 Financial Insights
PremiumCompany Announcements
Theravance Biopharma Outlines Growth Strategy at Investment Conference
Bulls Say, Bears Say
Bulls Say
Market Share GrowthYupelri's market share continues to grow, reaching all-time highs with 18.3% in the hospital LA-NEB market and 32% in the community share.
Milestone PaymentsTrelegy's strong growth increases the probability of Theravance receiving significant milestone payments, including a potential $50 million milestone.
Product IntegrationYupelri hospital accounts continue to increase, with over 2,000 hospitals ordering the product, and integration into hospitals' electronic medical record systems reduces promotional burden.
Bears Say
Cash Flow ExpectationsManagement no longer expects to achieve cash flow breakeven in the second half of 2024.
Drug DevelopmentThe trial for the key pipeline asset, ampreloxetine, has been delayed by over six months, raising concerns about the project's success.
Financial PerformanceTheravance Biopharma reported disappointing second-quarter results, with revenue 8% below consensus and EPS significantly lower than expected.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TBPH FAQ
What was Theravance Biopharma’s price range in the past 12 months?
Theravance Biopharma lowest stock price was $7.44 and its highest was $11.71 in the past 12 months.
What is Theravance Biopharma’s market cap?
Currently, no data Available
When is Theravance Biopharma’s upcoming earnings report date?
Theravance Biopharma’s upcoming earnings report date is Mar 03, 2025 which is in 71 days.
How were Theravance Biopharma’s earnings last quarter?
Theravance Biopharma released its earnings results on Nov 12, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.231 by -$0.029.
Is Theravance Biopharma overvalued?
According to Wall Street analysts Theravance Biopharma’s price is currently Undervalued.
Does Theravance Biopharma pay dividends?
Theravance Biopharma does not currently pay dividends.
What is Theravance Biopharma’s EPS estimate?
Theravance Biopharma’s EPS estimate is -$0.2.
How many shares outstanding does Theravance Biopharma have?
Theravance Biopharma has 49,174,297 shares outstanding.
What happened to Theravance Biopharma’s price movement after its last earnings report?
Theravance Biopharma reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.231. Following the earnings report the stock price went up 8.642%.
Which hedge fund is a major shareholder of Theravance Biopharma?
Among the largest hedge funds holding Theravance Biopharma’s share is Royce & Associates LLC. It holds Theravance Biopharma’s shares valued at 476K.
---
Theravance Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$11.25 (21.62% Upside)
$11.25 (21.62% Upside)
Blogger Sentiment
Bullish
TBPH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 4.2M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.65%
12-Months-Change
Fundamentals
Return on Equity
-22.88%
Trailing 12-Months
Asset Growth
-13.90%
Trailing 12-Months
Company Description
Theravance Biopharma
Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
---
TBPH Company Deck
---
TBPH Earnings Call
Q3 2024
0:00 / 0:00
---
TBPH Stock 12 Month Forecast
Average Price Target
$11.25
▲(21.62% Upside)
Technical Analysis
Best Analysts Covering TBPH
1 Year
1 Year Success Rate
5/16 ratings generated profit
1 Year Average Return
+1.85%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of +1.85% per trade.
---